the role of molecular driver identification continues to expand in nsclc
Published 4 years ago • 172 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
6:04
the future of driver mutations in nsclc
-
4:09
impact of driver mutations in nsclc
-
3:33
molecular drivers and therapeutic targets for neuroendocrine transformation in lung cancer
-
16:35
heterogeneity of nsclc and precipitating oncogenic driver mutations
-
4:38
molecular testing’s role in non–small cell lung cancer
-
26:57
segment 2: molecular targets in nsclc
-
51:17
different tests different drivers: the power of collaboration to solve a molecular mystery
-
2:55
lung cancer symptoms can often be subtle and easily overlooked, making early detection crucial
-
1:15
molecular testing recommendations for nsclc
-
6:22
gene mutations in nsclc
-
1:04:49
everything you need to know about molecular testing and targeted therapies in nsclc
-
3:30
understanding mutations and targeted therapy in lung cancer
-
1:13
identification of egfr mutations impact overall prognosis in lung cancers
-
1:23
targeting tumour drivers and resistance
-
47:10
ascp project echo® videoconference: key actionable driver mutations in patients with advanced nsclc
-
1:01:27
molecular testing for egfr mutations: what pathologists need to know
-
1:18:30
recent insights into the molecular biology & treatment of lung cancer
-
1:49
advanced lung cancer outlook is better than before
-
41:23
multimodal management of early-stage nsclc: egfr-targeted therapy in perioperative settings